INVIVID

About

Q&A

What is INVIVID's primary focus?

INVIVID is a biopharmaceutical company dedicated to providing protection from serious viral infectious diseases, initially focusing on SARS-CoV-2.

Where is INVIVID headquartered?

INVIVID is headquartered in New Haven, United States.

What technology platform does INVIVID utilize?

INVIVID deploys a proprietary integrated technology platform designed to assess, monitor, develop, and adapt to create best-in-class antibodies.

What types of diseases does INVIVID aim to address?

INVIVID is developing monoclonal antibody candidates for the prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into RSV and other high-need indications.

Who is the Interim Chief Executive Officer of INVIVID?

Jeremy Gowler was appointed as the Interim Chief Executive Officer of INVIVID in April 2024.

Who are some of the key executives at INVIVID?

Key executives at INVIVID include Robert Allen as Chief Scientific Officer, Jill Andersen as Chief Legal Officer & Corporate Secretary, and William Duke as Chief Financial Officer.

What is the primary sector of INVIVID?

INVIVID's primary sector is Biotechnology.

Team · 16

Marc Elia

Chairman of the Board

Robert Allen

Chief Scientific Officer

Jill Andersen

Chief Legal Officer & Corporate Secretary

William Duke

Chief Financial Officer

Rachael Gerlach

Senior Vice President of Regulatory Affairs

Julie Green

Chief Human Resources Officer

Timothy Lee

Chief Commercial Officer

Michael Mina

Chief Medical Officer and Chief Epidemiologist

Tamsin Berry

Director

Paul B. Bolno

Director

Terrance McGuire

Director

Kevin F. McLaughlin

Director

Ajay Royan

Director

Srishti Gupta

Director

Jeremy Gowler

Interim Chief Executive Officer

Dave Hering

Former CEO

Sectors & technology